中国生物工程杂志

［1］ Hogan W，Schubert D，LaBonte J，et a1．Speciesspecific　postentry barriers to primate immunodeficiency virus infection．J Viml，1999，73(12)：1020~1028 ［2］ Owens C M，Yang P C，Gotflinger H，et al．Human and simian immunodeficiency virus capsid proteins are major viral determinants of early postentry replication blocks in simian cells．J Virol，2003，77(1)：726~731 ［3］ Yap M W，Nisole S，Stoye J P．A single amino acid change in the SPRY domain of human TRIM5α leads to HIV-1 restriction．CurrBioZ，2005，15(1)：73~78 ［4］ Khazaeli M B, Conry R M, LoBuglio A F. Human response to monoclonal antibodies. J Immunother，1994, 15: 42~52 ［5］ Matthew Stremlau, Michel Perron, Sohanya Welikala．Species-specific variation in the B30.2(SPRY)domain of TRIM5α determines the potency of human immunodeficiency virus restriction．Journal of Virology, 2005, 79（ 5）：3139~3145 ［6］ 饶海林,张珂,曾海鹏,等.大肠杆菌表达的人IL-6复性条件研究. 微生物学免疫学进展，2007,35(3):27~29 Rao H L,Zhang K,Zeng H P, et al. Prog in Microbiol Immunol,2007,35(3): 27~29 ［7］ 金腾川，张瑞军，魏海明,等．重组人白细胞介素-18的高浓度复性、纯化和活性检测．中国生化药物杂志,2004,25(2)：67~71 Jin T C, Zhang R J, Wei H M,et al.Chinese Journal of Biochemical Pharmaceutics,2004,25(2):67~71 ［8］ Hassan Javanbakht, Wen Yuan, Darwin F. Characterization of TRIM5α TRIMerization and its contribution to human immunodeficiency virus capsid binding.Virology,2006, 353:234~246 ［9］ 李帷.生物超分子体系.北京:化学工业出版社，2003:225226 Li W. Biological Supramolecular System. Beijing:Chemical industry press, 2003:225~226 ［10］ 柴智,罗旭光,徐钧，等.乙型肝炎表面抗原单克隆抗体的制备及其应用.中国生物工程杂志,2008, 28(1): 70~75 Chai Z,Luo X G,Xu J,et al. China Biotechnology, 2008, 28(1): 70~75